[Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
This review illustrates the evolution in the clinical use of prostate specific antigen as a prostate cancer tumour marker. Because PSA lacks specificity, several new PSA parameters have been investigated such as the age-referenced PSA and the PSA density of the transition zone. We discuss also the molecular forms of PSA and the complexed PSA and new tumour markers which could be of interest in the future such as the HK2.
Zlotta
A
A
Service d'Urologie, Hôpital Erasme, U.L.B.
Schulman
C
C
D000328:Adult; D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000032:analysis*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D012680:Sensitivity and Specificity; D020840:Tissue Kallikreins / Q000032:analysis; D014662:Vasoconstrictor Agents / Q000032:analysis
D014408:Biomarkers, Tumor; D014662:Vasoconstrictor Agents; D020840:Tissue Kallikreins; D017430:Prostate-Specific Antigen